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Epidermal growth factor (EGF) family of growth fac-
tors and their receptors regulate normal and cancerous
epithelial cell proliferation, a process that can be sup-
pressed by antireceptor blocking antibodies. To identify
genes whose expression may be modulated by antirecep-
tor blocking antibodies, we performed a differential dis-
play screen with cells grown in the presence or absence
of antireceptor blocking antibodies; isolates from one
cDNA clone were 100% identical to human heterogene-
ous nuclear ribonucleoprotein K (hnRNP K), a protein
with a conserved KH motif and RGG boxes, has been
implicated in such functions as sequence-specific DNA
binding, transcription, RNA binding, and nucleocyto-
plasmic shuttling. Both EGF and heregulin-b1 induced
expression of hnRNP K mRNA and protein in human
breast cancer cells. This growth factor-mediated hnRNP
K expression was effectively blocked by pretreatment of
cultures with humanized anti-EGF receptor (EGFR) an-
tibody C225, or anti-human epidermal growth factor re-
ceptor-2 (HER2) antibody. Anti-EGFR monoclonal anti-
body also caused regression of human tumor xenografts
and reduction in hnRNP K levels in athymic mice. Sam-
ples from grade III human breast cancer contained more
hnRNP K protein than samples from grade II cancer.
Finally, overexpression of hnRNP K in breast cancer
cells significantly increased target c-myc promoter ac-
tivity and c-Myc protein, hnRNP K protein levels, and
enhanced breast cancer cell proliferation and growth in
an anchorage-independent manner. These results sug-
gested that the activity of human EGF receptor family
members regulates hnRNP K expression by extracellu-
lar growth promoting signals and that therapeutic hu-
manized antibodies against EGFR and HER2 can effec-
tively block this function.
Growth factors and their receptors play an important role in
regulating proliferation of epithelial cells. Abnormalities in the
expression, structure, or activity of their proto-oncogene prod-
ucts contribute to the development and pathogenesis of cancer.
For example, the human epidermal growth factor receptor,
HER1,1 is overexpressed in a large number of epithelial tumor
cells (1). HER2, the second member of the HER family, shares
extensive sequence homology with the tyrosine kinase domain
of HER1 (1–3) and is overexpressed, amplified, or both in a
number of human malignancies, including breast. Recently,
HER3 and HER4 have been added to this receptor family (2, 3).
Regulation of these receptor family members is complex, and
they can be trans-activated in a ligand-dependent manner. For
example, binding of heregulin-b1 (HRG) to HER3 or HER4 can
activate the HER2 as a result of HER2/HER3 or HER4/HER2
heterodimeric interactions (2–4). HER1 and HER2 have been
shown to induce transformation in recipient cells (2–4), possi-
bly because of excessive activation of signal transduction path-
ways. In contrast, transformation by HER3 or HER4 requires
the presence of HER1 or HER2 (5).
Since growth factors regulate the proliferation of cancer cells
by activating cell-surface receptors, one approach to controlling
cell proliferation is to use antireceptor-blocking monoclonal
antibodies to interfere with growth factor receptor-mediated
autocrine or paracrine growth stimulation (6). C225, the hu-
man murine chimeric antibody against the EGF receptor
(EGFR), blocks binding of ligand and prevents ligand-induced
activation of receptor tyrosine kinase (6, 7). C225 therapy has
been success in phase I and phase IIA multicenter clinical
trials in combination with chemotherapy or radiation (8–11).
Similarly, the humanized form of anti-HER2 recombinant
monoclonal antibody (HCT) inhibits the growth of breast can-
cer cells overexpressing HER2 (12) and is currently being used
as an effective drug against breast cancer both alone (13) and in
combination with chemotherapy (14). Antireceptor antibodies
inhibit many processes, including mitogenesis, cell-cycle pro-
gression, invasion and metastasis, angiogenesis, and DNA re-
pair (8).
In eukaryotic cells, heterogeneous nuclear RNAs (hnRNAs),
from which mRNAs are generated by RNA processing, associ-
ate with specific nuclear proteins to form large hnRNP com-
plexes (15, 16). These hnRNP proteins bind pre-mRNAs and
are believed to play important roles in mRNA biogenesis (17,
18), nucleocytoplasmic transport of mRNA (19–21), and cyto-
plasmic mRNA trafficking (22). To date, about 20 hnRNPs (A
through U) have been identified. HnRNP K, the major poly(iC)-
binding protein, has several structural features not shared
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with other hnRNP proteins (23). For example, the binding of
hnRNP K to nucleic acid is mediated by three repeat motifs
termed the KH (K homology) domains rather than by the con-
sensus RNA-binding sequence found in other hnRNP proteins
(23, 24). The KH domain is an evolutionarily conserved RNA-
binding motif also found in fragile X protein FMR1 (25), meio-
sis-specific splicing factor MER1 (26), and paraneoplastic Ri
autoantigen (27). In addition, hnRNP K binds single-stranded
DNA in vitro (28) and has been identified as a sequence-specific
DNA-binding protein (29), consistent with its proposed role in
transcription. More recently, hnRNP K has been shown to bind
to a cis-element in the human c-myc promoter (30) and to
activate c-myc expression (31) by promoting the synthesis of
c-myc mRNA from a reporter gene (32). The hnRNP K protein
can also interact with some proto-oncogene products and to act
as a docking platform in signal transduction cascades (33, 34).
The potential involvement of hnRNP in transformation was
suspected, four splice variants of hnRNP K are up-regulated in
SV40-transformed cells (35), and hnRNP B1 is the only other
member of the hnRNP family, beside hnRNP K that is overex-
pressed in human lung cancers (36). Despite the widely be-
lieved involvement of hnRNP K in post-transcriptional control,
its possible regulation by the EGF family and by therapeutic
antireceptor antibodies remains unexplored.
To identify genes whose expression may be modulated by the
activity of the EGF family of receptors because of ligand-in-
duced activation of receptor tyrosine kinases or inhibition of
receptor-associated tyrosine kinase activation, we used a hu-
man cDNA array approach to isolate cDNAs differentially ex-
pressed in the presence and absence of antireceptor antibodies.
We identified one clone that was identical to human hnRNP K.
In human breast cancer cells, EGF and HRG induced hnRNP K
mRNA and protein expression that could be effectively blocked
by pretreatment with antireceptor monoclonal antibodies. Our
results also suggested that hnRNP K is involved in EGF- or
HRG-induced transcription from the c-myc promoter and that
hnRNP K expression can be used as a molecular monitor to
assess the anti-tumor action of therapeutic antireceptor
agents.
EXPERIMENTAL PROCEDURES
Cell Cultures and Reagents—Human colon cancer DiFi and FET
cells, and breast cancer MCF-7, MDA-468, BT-474, SK-BR3, MDA-231,
and MDA-435 cells and vulvar carcinoma A431 cells, were maintained
in Dulbecco’s modified Eagle’s medium-F-12 (1:1) supplemented with
10% fetal calf serum. C225 and HCT ware provided by Imclone Sys-
tems, Inc. and Genentech Inc., respectively. Recombinant HRG-b1 was
purchased from Neomarkers, Inc. Anti-vinculin antibody and recombi-
nant EGF was purchased from Sigma. Polyclonal and monoclonal an-
tibodies against hnRNP K were generously provided by Drs. Pradip
Raychaudhuri and Gideon Dreyfuss (32, 23).
Gene Discovery Array Screening—DiFi and FET cells were cultured
with or without C225 for 10 h, and total RNA was isolated using
TRIZOL reagent (Life Technologies, Inc.). Poly(A) RNA was isolated
using a poly(A) RNA isolation kit (Invitrogen). Gene discovery array
(GDA) filters (version 1.2) containing 18,376 nonredundant human
cDNA clones were purchased from Genome Systems. Probe preparation
and hybridization conditions were performed according to manufactur-
er’s recommendations. In brief, 2 mg of poly(A) RNA was reverse-
transcribed using T18MN primer (Genome Systems) and Superscript II
reverse transcriptase (Life Technologies, Inc.) in the presence of
[33P]dCTP. cDNA was purified using a G-50 spin column, treated with
0.25 M NaOH to remove RNA, and neutralized with Tris. Identical
filters were hybridized to cDNA probes in 50% formamide buffer at
42 °C for 16 h, washed two times with 23 SSC, and washed two more
with 0.63 SSC. Filters were exposed to a phosphoimager, and images
were quantitated by the bioinformatics department at Genome Systems
using Array Vision software. Normalized intensity values for control
and C225-treated filters were compared with determine -fold induction.
Cell Extracts, Immunoblotting, and Immunoprecipitation—To pre-
pare cell extracts, cells were washed three times with phosphate-buff-
ered saline and lysed in buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl,
0.5% Nonidet P-40, 100 mM NaF, 200 mM NaVO5, 1 mM PMSF, 10 mg/ml
leupeptin, 10 mg/ml aprotinin) for 15 min on ice. The lysates were
centrifuged in an Eppendorf centrifuge at 4 °C for 15 min. Cell lysates
FIG. 1. Identification of hnRNP K as an antireceptor antibody-regulated gene. A, representative differential display patterns of
antireceptor-regulated spots on the GDA filters. Human colon DiFi and FET cells were treated with C225 (50 nM) for 10 h. Total RNAs were isolated
and used for hybridization with the GDA array filters, as described under ”Experimental Procedures.“ Results are presented as percent change by
antibody treatment over control (CON) untreated cells. B, MDA231 cells were treated with or without 30 nM TGF-a in the absence or presence of
30 nM C225 or IgG for 30 min. Cell lysates were immunoprecipitated with an anti-EGFR mAb 528 and immunoblotted with anti-phosphotyrosine
mAb 4G10, and the position of EGFR is shown by an arrow. Sequentially, the above blot was reprobed with an anti-EGFR mAb to demonstrate
the levels of EGFR in different tubes. C, tumor cell lines were treated with or without C225 or HCT or IgG (50 nM) for 16 h. Total RNA was isolated,
and the expression of hnRNP K mRNA was detected by Northern hybridization. Results are representative of three experiments. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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containing equal amounts of protein were resolved by SDS-PAGE,
transferred to nitrocellulose, and probed with the appropriate antibod-
ies. Equal numbers of cells were metabolically labeled for 4–8 h with
100 mCi/ml [35S]methionine in methionine-free medium containing 2%
dialyzed fetal bovine serum in the absence or presence of indicated
treatments. Cell extracts containing equal trichloroacetic acid percep-
tible counts were resolved on SDS-PAGE, immunoprecipitated with the
desired antibody, and analyzed after exposure to film.
Northern Hybridization—Total cytoplasmic RNA was isolated using
the TRIZOL reagent, and 20 mg of RNA was analyzed by Northern
hybridization using a cDNA fragment of human hnRNP K. Ribosomal
RNA (28 and 18 S) was used to assess the integrity of the RNA and for
RNA-loading controls; blots were also routinely reprobed with control
glyceraldehyde-3-phosphate dehydrogenase cDNA.
Human Tissue Samples—Human breast tissue samples were ob-
tained from a tissue bank maintained by Dr. Luis Costa (Hospital de
Santa Maria, Lisbon, Portugal). Specimens derived from patients who
had undergone surgery for breast cancer were frozen in liquid nitrogen
and stored at 280 °C, as described previously (37). Thawed tissue
samples were homogenized in Triton X-100 lysis buffer (20 mM HEPES,
150 mM NaCl, 1% Triton X-100, 0.1% deoxycholate (v/w), 2 mM EDTA,
2 mM EDTA, 2 mM sodium orthovanadate, and protease inhibitor mix-
ture (Roche Molecular Biochemicals), and equal amounts of proteins
were analyzed by Western blotting.
Xenografts Studies—A431 cells (107) were implanted subcutaneously
into nude mice and allowed to grow for 8 days. The mice were given
intraperitoneal injections of either phosphate-buffered saline or C225, 1
mg/mouse, twice a week for 3 weeks. Treatment of C225 alone resulted
in transient inhibition of tumor growth. Tumor size was measured twice
weekly with calipers, using the formula p/6x larger diameter 3 (smaller
diameter).
RESULTS AND DISCUSSION
Identification of hnRNP K as an Antireceptor Antibody-reg-
ulated Gene—In an attempt to identify genes whose expression
may be modulated in human cancer cells by antireceptor anti-
bodies that block receptor activity, we used GDA filters human
version 1.2 obtained from Genome Systems. GDA is a single
nylon filter spotted with 18,376 nonredundant human cDNA
clones chosen from the Integrated Molecular Analysis of Ge-
nome and Expression collection. We have initially used two cell
lines: high EGFR overexpressing DiFi cell line and a moderate
EGFR expressing FET cell line (38). Cells were cultured with or
without anti-EGF receptor antibody C225 for 10 h, total RNA
was isolated, and cDNA probes were prepared using reverse
transcription. The filters were hybridized and exposed to a
phosphoimager. Phosphoimager scans were sent to Genome
Systems, and their Bioinformatics Department used Array Vi-
sion software to analyze differential expression of genes. This
analysis identified several differentially expressed gene prod-
ucts. Representative data for 11 genes whose expression was
altered are shown in Fig. 1. To further characterize these
antibody-responsive genes, we obtained expressed sequence
tag clones arrayed on GDA filters from Genome Systems. While
using the cDNAs obtained, we uncovered the problem that the
clones received from Genome Systems did not sequence verify
to data base numbers, and we got mixed results in our North-
ern blots. Upon contacting Genome Systems, we found that
their GDA version 1.2 filters were not sequence-verified, were
developed on the basis of information from Integrated Molecu-
lar Analysis of Genome and Expression consortium clones, and
were expected to have mixed colony stocks. (GDA1.2 filters are
discontinued due to these problems). To resolve this issue, we
isolated multiple single colonies from each clone stock and
analyzed them by Northern analysis. Northern analysis of sin-
gle colony-isolated cDNAs showed that one of the cDNAs was
down-regulated by antibody treatment. Sequencing of the
cDNA revealed that it had extensive similarity with hnRNP K;
however it possessed an extra region of 400 base pairs, sug-
gesting that this was an isoform of hnRNP K. Since these
expressed sequence tag clones were isolated from fetal liver, we
screened a mammary gland cDNA library (CLONTECH) with
the 1.1-kilobase pair cDNA probe to verify that this isoform of
hnRNP K was expressed in the mammary gland. Ten positive
clones were isolated and sequenced. Comparison of the se-
quences with the GenBankTM revealed that the sequences were
100% identical to human hnRNP K gene.
To confirm that the hnRNP K gene was regulated by growth
factors in mammary epithelial cells, regulation of the hnRNP K
gene expression by antibodies was verified by experiments
involving Northern analysis using the full-length cDNA (1.8
kilobase pairs) isolated from mammary gland (hnRNP K, iden-
tical GenBankTM to accession number S74678). A431 cells,
which overexpress EGFR, are growth-stimulated by autocrine
transforming growth factor-a (TGF-a) and growth-inhibited by
C225 (6, 7). To determine the role of growth factor receptor
activity in the regulation of hnRNP, we asked whether C225
could down-regulate the steady-state level of hnRNP K mRNA.
FIG. 2. Regulation of hnRNP K mRNA expression by growth
factors. Breast cancer MCF-7 (A), and colon cancer LS174T and
CaCO2 cells (B) were treated with HRG (30 nM) for the indicated times.
Total RNA was isolated, and hnRNP K mRNA levels were detected by
Northern blot analysis. Subsequently, the blot was reprobed with a
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe.
Quantitation of mRNA is shown in the bottom panels. Results are
representative of two experiments.
FIG. 3. Antireceptor antibodies and growth factors modulate hnRNP K protein level. A, cells were treated with C225 or HCT (50 nM)
for 16 h (A) and EGF or HRG (30 nM) for the indicated times (B). Total lysates were run on SDS-PAGE and blotted with anti-hnRNP K mAb.
Anti-vinculin Ab was used as an internal control. Quantitation of the ratio of hnRNP K: vinculin is shown in the bottom panel. Results are
representative of three experiments.
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Earlier studies from this laboratory have shown the effective-
ness of 225 antibody to inhibit TGF-a- or EGF-induced tyrosine
phosphorylation of EGFR in DiFi, FET, A431, MDA468, and
mouse NIH3T3 cells stably expressing human EGFR (38–41).
Consistent with these reports, C225 also blocked the ability of
EGF to stimulate the tyrosine phosphorylation of EGFR in
MDA231 cells (Fig. 1B). Treatment of A431 or MDA468 cells
with C225, but not control IgG, resulted in a decrease in
hnRNP K mRNA expression (Fig. 1C). Similarly, HCT treat-
ment of BT-474 or SKBR3 cells, which overexpress HER2, was
associated with reduced expression of hnRNP K mRNA (Fig.
1C). We have earlier demonstrated the ability of anti-HER2
antibody to suppress the tyrosine phosphorylation of HER2 in
BT-474 and SKBR3 cells (42).
Regulation of hnRNP K Expression by Growth Factors—
Since MDA-231 cells are known to constitutively secrete HRG,
a ligand for HER3 and HER4 that can transactivate EGFR and
HER2, the above results raised the possibility of HRG regula-
tion of hnRNP K mRNA expression. HRG treatment of human
breast cancer MCF-7 (38), and colorectal cancer LS174 and
CaCO2 cells (39), was accompanied by increased expression of
hnRNP K mRNA (Fig. 2, A and B). EGF regulation of hnRNP
K mRNA expression was also confirmed using a mouse NIH3T3
cell line (HER14) that stably expressed human EGFR, lack
production of TGF-a, and to exogenous EGF by growth stimu-
lation (40). EGF treatment of HER14 cells for 8 h was accom-
panied by a significant increase in hnRNP K mRNA levels
(data not shown). Taken together, these results suggest that
EGF, HRG, and antireceptor monoclonal antibodies, which in-
terfere with EGFR and HER2, modulate hnRNP K mRNA
levels in a number of cell types.
Western blot analysis was performed to determine whether
the modulation of hnRNP K mRNA levels by growth factors
and antireceptor monoclonal antibodies was associated with a
corresponding modulation in the expression of hnRNP K pro-
tein. Results demonstrated that A431 cells and human colon
carcinoma DiFi cells, which have functional TGF-a autocrine
loop (38), expressed a lower level of the 65-Da hnRNP K pro-
tein, after C225 treatment (Fig. 3A). Similarly, HCT inhibited
hnRNP K protein levels in BT-474 cells (Fig. 3A). In contrast,
treatment of MCF-7 cells with EGF or HRG significantly in-
creased the level of hnRNP K protein (Fig. 3B).
C225 Therapy Modulates hnRNP K Expression in a Xe-
nograft Model—Our results presented above suggest that
hnRNP K expression is positively regulated by growth factors
and can be reduced by antireceptor-blocking antibodies. To
further understand the significance of hnRNP K expression in
tumor cell growth regulation, we next examined the effect of
C225 therapy on the status of hnRNP K expression in in vivo
setting using the A431 xenograft model. As expected, C225
treatment of well established A431 cell xenografts was associ-
FIG. 4. Anti-EGF receptor antibody C225 suppresses hnRNP K
expression in a tumor xenograft model. A, established A431 cells
xenografts (0.6–0.8 cm3) were treated with C225 (100 mg/animal, 2
times a week) or saline for 21 days. Tumor volumes in the control and
C225-treated groups at day 29 are shown. B, histology of tumors as
assessed by H&E staining. C, total RNA was isolated from four control
and five antibody-treated tumors. The expression of hnRNP K was
immediately analyzed by Northern hybridization. GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase. D, tissue lysates from four control
(C1–C4) and six antibody-treated (T1–T6) tumors were immediately
immunoblotted with an anti-hnRNP mAb. The blots were reprobed with
a control vinculin antibody.
FIG. 5. Expression of hnRNP K in multiple organs and human
breast tumors. A, expression profile of hnRNP K mRNA in multiple
mouse organs as determined by the Northern hybridization. Ribosomal
28 S and 18 S RNAs were used to assess the integrity of RNA samples.
Lanes: 1, muscle; 2, liver; 3, heart; 4, thymus; 5, colon; 6, kidney; 7,
cerebral cortex; 8, placenta; 9, spleen; 10, cerebellum; 11, uterus; 12,
stomach; 13, ovary; 14, testis; 15, salivary gland; 16, lung; 17, adrenal
gland. B, tissue lysates from grade II and grade III were analyzed by
immunoblotting for hnRNP K expression (upper panel) and, subse-
quently, reprobed with a vinculin Ab as a loading control (middle
panel). Quantitation of the ratio of hnRNP K: vinculin is shown in the
bottom panel.
FIG. 6. Regulation of c-Myc expression by growth factors and
antireceptor antibodies. A, modulation of c-Myc promoter activity by
hnRNP K and HRG. MCF-7 cells were transiently transfected with a
DNA for luciferase drawn by c-Myc promoter and hnRNP K or control
(Con) DNA, and luciferase activity was measured 24 h after transfec-
tion. Some cultures were treated with HRG (30 nM) for 16 h before lysis.
Relative luciferase activity is shown in the bottom panel. B, tumors cells
were treated with C225 or HCT (50 nM) for 16 h, and c-Myc mRNA
expression was measured by Northern hybridization. GAPDH, glycer-
aldehyde-3-phosphate dehydrogenase. Results are representative of
two experiments.
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ated with a reduced regression of tumors (Fig. 4A) and appear-
ance of very smooth boundaries between tumors and surround-
ing tissues compared with control untreated tumors (Fig. 4B).
Importantly, significant reductions in the levels of hnRNP K
mRNA (Fig. 4C) and hnRNP K protein (Fig. 4D) accompanied
C225 therapy.
hnRNP K Expression in Human Breast Cancer—Since these
results show that hnRNP K expression is regulated by growth
factors, we explored whether there is any relationship between
the proliferation state in murine and human tissue and hnRNP
K expression. Northern blot analysis of multiple mice tissues
revealed the presence of low levels of hnRNP K mRNA in all
tissues. However, the hnRNP K transcript levels were signifi-
cantly higher in tissues such as cerebellum, ovary, and testis
(Fig. 5A). Interestingly, there was expression of only the faster
migrating form of hnRNP K mRNA in testes (Fig. 5A, lane 14).
We also examined the expression of hnRNP K in a small num-
ber of human breast carcinoma biopsy samples (37). In general,
grade III tumor specimens had a higher level of hnRNP K
protein compared with grade II tumor specimens (Fig. 5B).
Additional studies utilizing large number of clinical samples
are needed to confirm these findings.
Effect of hnRNP K on the Biology of Breast Cancer Cells—
Data from several recent reports indicate that c-myc, a growth
factor-inducible early gene, is one of the downstream targets of
hnRNP K (32). We verified the potential role of hnRNP K in
growth factor-mediated stimulation of transcription from the
c-myc promoter using a luciferase reporter gene containing
c-Myc promoter. As expected, cotransfection of hnRNP K up-
regulated the c-Myc promoter activity (Fig. 6A). Treatment of
cells with antireceptor antibodies resulted in a significant de-
creased level of c-myc mRNA (Fig. 6B).
To further delineate the potential contribution of hnRNP K
in breast cancer cells, we next established stable MCF-7 clones
expressing T7-tagged hnRNP K or control vector (Fig. 7A). As
expected from the data in Fig. 6, cells expressing hnRNP K also
exhibited an increased level of c-Myc (Fig. 7A) as well as stim-
ulation of transcription from the c-myc promoter (Fig. 7B). To
examine the potential influence of hnRNP K expression on the
growth characteristics of breast epithelial cancer cells, we
measured the proliferation rate and ability of cells to grow in
an anchorage-independent manner. Expression of hnRNP K
significantly enhanced the proliferation rate of MCF7 cells
(Fig. 7C). Overexpression of hnRNP K was accompanied by a
significant reproducible enhancement of the ability of cells to
form larger colonies in soft agar as compared with those formed
by vector transfected control cells (Fig. 7D). Together, these
observations suggested that breast cancer cells expressing
hnRNP K have altered growth characteristics.
In summary, we provide new evidence that the hnRNP K is
a target of growth factor in human cancer cells and that hnRNP
K positively controls the growth rate of human breast cancer
cells. This conclusion is based on the following evidence: 1)
up-regulation of hnRNP K mRNA and protein by both HRG
and EGF in cells with low levels of EGF and HER2 receptors;
2) down-regulation of hnRNP K mRNA and protein by HCT
and C225 in cells with high levels of EGF and HER2 receptors;
3) blockage of ligand-induced stimulation of hnRNP K by an
antireceptor antibody in breast cancer cells with low levels of
receptors; 4) a reduction in the level of hnRNP K in tumor
xenografts treated with C225; 5) deregulation of hnRNP K
expression cells leads to an enhancement of the proliferation
and anchorage-independent growth of breast cancer cells; and
finally, 6) human breast tumor specimens from grade III tu-
mors exhibited an increased level of hnRNP-K protein com-
pared with the levels in grade II tumors.
The molecular mechanisms by which hnRNP K affects the
growth rate of human cells are not clear at the moment. hnRNP
K has been shown to activate the human c-Myc promoter (32)
and increases the level of c-Myc protein. Enhanced expression
of c-Myc could enable this transactivation factor to stimulate
its downstream targets genes, leading to cell cycle progression.
In addition, hnRNP K physically interacts with several onco-
gene products, including members of the Src protein tyrosine
kinases (33, 34), and this could also contribute to the mitogenic
response. Our demonstrated growth-promoting function of
hnRNP K protein in human breast epithelial cells also supports
the observation of hnRNP K up-regulation in SV40-trans-
formed cells (35). In contrast to these findings, there are re-
ports showing a repressing effect of hnRNP on C/EBP-b-medi-
ated activation of the agp gene involved in the acute phase
response (43) and induction of programmed cell death in imag-
inal discs of Drosophila (44). These observations suggest that
the hnRNP K may differently influence cellular functions in a
cell type-specific manner.
In summary, our findings have clearly demonstrated for the
FIG. 7. Effect of hnRNP K expression on the biology of breast cancer cells. A, Western blot analysis of control and T7-tagged hnRNP K
clones by anti-T7 mAb. The blot was reprobed with an anti-vinculin Ab, as a loading control, and, subsequently, with an anti-cMyc mAb. B, effect
of T7-hnRNP K expression on the activity of the c-Myc promoter-luciferase. C, effect of T7-hnRNP K expression on the growth rate of cells by MTT
assay. D, effect of T7-hnRNP K expression on anchorage-independent growth of MCF-7 cells. E, representative photographs of soft agar colonies
(n 5 3).
Growth Factor Regulation of hnRNP K 9703
 by guest on M
arch 14, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
first time a potential role of hnRNP K in the actions of HER
growth factors that are widely deregulated in human cancers
and that ligand-dependent hnRNP K expression can be effec-
tively inhibited with antireceptor blocking antibodies C225 and
HCT. In addition, we also provide new evidence that hnRNP K
may contribute to regulating target genes that lead to en-
hanced growth rate of cancer cells.
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